China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Britain Courts Anthropic Amid US Defense Department Dispute 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
PARSIPPANY, N.J., Sept. 20, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the 2017 Cantor Fitzgerald Global Healthcare Conference at 10:20 AM ET on Tuesday, September 26, 2017 in New York City.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco (973) 451-4030 [email protected]
